. Author manuscript; available in PMC: 2017 Dec 1.

Published in final edited form as: Liver Int. 2016 Jul 6;36(12):1783–1792. doi: 10.1111/liv.13177

Table 2.

Adverse Events

	All (n=18)	HCV (n=6)	HIV/HCV (n=8)	HIV (n=4)
Any treatment-emergent adverse event, number of participants (% cohort)	16 (89%)	5 (83%)	7 (88%)	4 (75%)
Grade 3 and 4 treatment-related adverse events, number of participants (% cohort)
Migraine headache	1 (6%)	0	1 (12%)	0
Elevated ALT	1 (6%)	0	0	1 (25%)
Increased lipase	4 (22%)	1 (17%)	1 (12%)	2 (50%)
Increased amylase	2 (11%)	1 (17%)	0	1 (25%)
Discontinuation owing to adverse event	0	0	0	0
Serious adverse event, number of participants (% cohort)	1^* (12%)	0	1^* (12%)	0

One participant experienced abdominal pain and vomiting following post-treatment liver biopsy and was admitted for pain control and monitoring. Course was complicated by fever and gram-negative bacteremia.